Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

Cancer

Volumn 121, Issue 4, 2015, Pages 556-561

  Issa, Jean Pierre ^a   Garcia Manero, Guillermo ^b   Huang, Xuelin ^b   Cortes, Jorge ^b   Ravandi, Farhad ^b   Jabbour, Elias ^b   Borthakur, Gautam ^b   Brandt, Mark ^b   Pierce, Sherry ^b   Kantarjian, Hagop M ^b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute myelogenous leukemia; Decitabine; Histone deacetylase; Hypomethylating agents; Inhibitors; Myelodysplastic syndrome; Trials; Valproic acid

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; VALPROIC ACID; ANTINEOPLASTIC AGENT; AZACITIDINE; DECITABINE; HISTONE DEACETYLASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BAYES THEOREM; CANCER REGRESSION; CANCER SURVIVAL; CONFUSION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SCREENING; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART DISEASE; HUMAN; INFECTION; KIDNEY DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROPATHY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; SOMNOLENCE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG ADMINISTRATION; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; BAYES THEOREM; DRUG ADMINISTRATION SCHEDULE; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME; VALPROIC ACID;

EID: 84922513553     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29085     Document Type: Article

References (24)

1. Faderl S, Kantarjian H. Myelodysplastic syndromes. In: DeVita V, Lawrence T, Rosenberg S, eds. Cancer Principles and Practice of Oncology. 9th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2011:1988-1996.
2. Silverman L. The myelodysplastic syndrome. In: Hong WK, Blast RC, Hait WN, et al, eds. Cancer Medicine. 8th ed. Shelton, CT: People's Medical Publishing House-USA; 2010:1544-1558.
3. Foran JM, Sekeres MA. Myelodysplastic syndromes. In: Aberloff M, Armitage J, Niederhuber J, Kastan M, McKenna W, eds. Abeloff's Clinical Oncology. 4th ed. Philadelphia, PA: Churchill Livingstone; 2008:2235-2259.
4. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
5. Greenberg P, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120:2454-2465.
6. Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008;113:1351-1361.
7. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20:2429-2440.
8. Fenaux P, Mufti G, Hellstrom-Lindberg E, et al. Efficacy of azacitidine (AZA) compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label, phase III study. Lancet Oncol. 2009;10: 223-232.
9. Kantarjian H, Issa JP, Rosenfeld C, et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer. 2006;106:1780-1794.
10. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;198:52-57.
11. Kantarjian H, O'Brien S, Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome. Cancer. 2007;109:1133-1137.
12. Steensma D, Baer M, Slack J, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 2009;27:2842-3848.
13. Kebriaei P, Champlin R, de Lima M, Estey E. Management of acute leukemias. In: DeVita V, Lawrence T, Rosenberg S, eds. Cancer Principles and Practice of Oncology. 9th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2011:1928-1954.
14. Schiffer CA, Stone RM. Acute myeloid leukemia in adults: mast cell leukemia and other mast cell neoplasms. In: Hong WK, Blast RC, Hait WN, et al, eds. Cancer Medicine. 8th ed. Shelton, CT: People's Medical Publishing House-USA; 2010:1559-1581.
15. Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20:6969-6978.
16. Kuendgen A, Strupp C, Aivado M, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood. 2004;104:1266-1269.
17. Garcia-Manero G, Assouline S, Cortes J, et al. Phase I study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 2008;112:981-989.
18. Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SA HA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008;111:1060-1066.
19. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007;110:2302-2308.
20. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108:3271-3279.
21. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642-4649.
22. Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006;5:27-36.
23. Prebet T, Sun Z, Figueroa ME, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J Clin Oncol. 2014;32:124-1248.
24. Quintas-Cardama A, Kantarjian H, Ravandi F, et al. Very high rates of clinical and cytogenetic response with the combination of the histone deacetylase inhibitor pracinostat (SB939) and 5-azacitidine in high-risk myelodysplastic syndrome [abstract]. Blood (ASH Annual Meeting Abstracts). 2012;120:3821.